![Uli Bialucha](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Uli Bialucha
Directeur Technique/Scientifique/R&D chez
XILIO THERAPEUTICS, INC.
Profil
Uli Bialucha is currently Chief Scientific Officer at Xilio Therapeutics, Inc. since 2022.
Formerly, Dr. Bialucha was Vice President-Drug Discovery at Immunitas Therapeutics, Inc. from 2019 to 2021.
Education includes an undergraduate degree from the University of Sussex and a doctorate from University College London.
Postes actifs de Uli Bialucha
| Sociétés | Poste | Début |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/04/2021 |
Anciens postes connus de Uli Bialucha
| Sociétés | Poste | Fin |
|---|---|---|
Immunitas Therapeutics, Inc.
 Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Develops single cell genomic-based drugs | Corporate Officer/Principal | 01/04/2021 |
Formation de Uli Bialucha
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
2
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
University of Sussex
 University of Sussex Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Immunitas Therapeutics, Inc.
Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Develops single cell genomic-based drugs | Health Technology |
